JP2020514315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514315A5 JP2020514315A5 JP2019540420A JP2019540420A JP2020514315A5 JP 2020514315 A5 JP2020514315 A5 JP 2020514315A5 JP 2019540420 A JP2019540420 A JP 2019540420A JP 2019540420 A JP2019540420 A JP 2019540420A JP 2020514315 A5 JP2020514315 A5 JP 2020514315A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalkyl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 229910052801 chlorine Inorganic materials 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 238000006243 chemical reaction Methods 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 210000002816 gill Anatomy 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- -1 NC- Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17153390 | 2017-01-26 | ||
| EP17153390.4 | 2017-01-26 | ||
| PCT/EP2018/051390 WO2018138030A1 (en) | 2017-01-26 | 2018-01-22 | Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514315A JP2020514315A (ja) | 2020-05-21 |
| JP2020514315A5 true JP2020514315A5 (enExample) | 2021-01-14 |
| JP7050792B2 JP7050792B2 (ja) | 2022-04-08 |
Family
ID=57906579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540420A Active JP7050792B2 (ja) | 2017-01-26 | 2018-01-22 | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10603317B2 (enExample) |
| EP (1) | EP3573969A1 (enExample) |
| JP (1) | JP7050792B2 (enExample) |
| CN (1) | CN110312714B (enExample) |
| WO (1) | WO2018138030A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7049349B2 (ja) * | 2017-01-26 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| WO2018138026A1 (en) * | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110198928B (zh) * | 2017-01-26 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628476A (en) | 1898-03-18 | 1899-07-11 | Joseph Howard Kirk | Junction of cycle, motor-car, or other frames, &c. |
| US2505322A (en) | 1945-09-14 | 1950-04-25 | Gibson Refrigerator Co | Refrigerator cabinet |
| US2560111A (en) | 1946-11-07 | 1951-07-10 | Raymond T Levine | Buffing chuck |
| US2656003A (en) | 1948-02-27 | 1953-10-20 | Inst Of Inventive Res | High explosive disk-shaped charge for seismic exploration |
| US2727340A (en) | 1953-08-31 | 1955-12-20 | Alfred S Zanotta | Portable tool for reconditioning crane rails |
| US5356287A (en) | 1987-03-16 | 1994-10-18 | Mcintyre Kevin M | Simulating presence |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP2008530162A (ja) | 2005-02-15 | 2008-08-07 | グラクソ グループ リミテッド | グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用 |
| CA2602566A1 (en) | 2005-03-28 | 2006-10-05 | Pfizer Inc. | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
| US7664629B2 (en) | 2005-07-19 | 2010-02-16 | Xerox Corporation | Second language writing advisor |
| EP1916234B1 (en) * | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| WO2007104717A1 (en) | 2006-03-15 | 2007-09-20 | Neurosearch A/S | Quinazolinones and their use as potassium channels activators |
| EP2006271A4 (en) | 2006-03-30 | 2011-08-10 | Asahi Kasei Pharma Corp | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| TW200838526A (en) * | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| ES2345916B1 (es) | 2008-10-14 | 2011-09-14 | Clipdorfix, S.L. | Dispositivo de fijacion liberable de elementos adosados. |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| KR101712576B1 (ko) * | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| US20110269783A1 (en) | 2008-11-10 | 2011-11-03 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| JP2012136438A (ja) * | 2009-04-22 | 2012-07-19 | Astellas Pharma Inc | テトラゾール化合物 |
| US20120172351A1 (en) | 2009-06-09 | 2012-07-05 | Nobuyuki Negoro | Novel fused cyclic compound and use thereof |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| EP2646425B1 (en) | 2010-12-01 | 2015-06-10 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| WO2014019186A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| HK1210144A1 (en) | 2012-11-28 | 2016-04-15 | 勃林格殷格翰国际有限公司 | New indanyloxydihydrobenzofuranylacetic acids |
| JP6283862B2 (ja) | 2012-12-07 | 2018-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
| AU2014221489B2 (en) * | 2013-02-28 | 2018-03-08 | Tiumbio Co., Ltd. | Tricyclic compound and use thereof |
| WO2015024526A1 (en) | 2013-08-23 | 2015-02-26 | Fujian Haixi Pharmaceuticals Co., Ltd | Carboxylic acid compounds in treatment of diabetes mellitus |
| WO2018138026A1 (en) * | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7049349B2 (ja) * | 2017-01-26 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| US10919859B2 (en) * | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110198928B (zh) * | 2017-01-26 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 |
| JP7049353B2 (ja) | 2017-02-08 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
-
2018
- 2018-01-22 JP JP2019540420A patent/JP7050792B2/ja active Active
- 2018-01-22 WO PCT/EP2018/051390 patent/WO2018138030A1/en not_active Ceased
- 2018-01-22 EP EP18703223.0A patent/EP3573969A1/en not_active Ceased
- 2018-01-22 CN CN201880008301.5A patent/CN110312714B/zh active Active
- 2018-01-22 US US16/479,227 patent/US10603317B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505402A5 (enExample) | ||
| JP2020506205A5 (enExample) | ||
| JP2020505400A5 (enExample) | ||
| JP2020505393A5 (enExample) | ||
| JP2020505394A5 (enExample) | ||
| JP2019535792A5 (enExample) | ||
| JP2018526405A5 (enExample) | ||
| JP2018526352A5 (enExample) | ||
| JP2019532110A5 (enExample) | ||
| JP2017508789A5 (enExample) | ||
| JP2023052094A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| JP2016534084A5 (enExample) | ||
| JP2009532453A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| JP2018522879A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| JP2014502988A5 (enExample) | ||
| JP2017503760A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| JP2016506958A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2015509102A5 (enExample) |